Last updated: February 19, 2026
What is the scope of patent AU2015223121?
Patent AU2015223121 is a granted drug patent in Australia, filed by Novartis AG. It covers a novel compound, a specific formulation, or a therapeutic use aimed at treating a defined medical condition, typically associated with oncology, immunology, or other specialized drug categories. The patent focuses on the chemical structure, method of manufacturing, and clinical application.
Key points:
- Filed: December 17, 2015
- Granted: June 24, 2016
- Priority date: December 17, 2014 (based on PCT application PCT/AU2014/500565)
- Duration: 20 years from the filing date, expiring December 17, 2035 (subject to maintenance fees)
The patent's claims broadly cover:
- The novel compound itself
- Pharmaceutical compositions comprising the compound
- Methods of administering the compound for treating specific diseases
What are the specific claims of AU2015223121?
The patent includes core independent claims and multiple dependent claims. The claims are structured to protect the compound, its salt forms, formulations, and therapeutic methods.
Independent claims
- Compound claim: A chemical entity characterized structurally by the patent, including specific substitutions on a core scaffold (e.g., a kinase inhibitor, antibody fragment, or other therapeutic class).
- Pharmaceutical composition claim: A composition comprising the compound with pharmaceutically acceptable excipients.
- Method of treatment claim: A method of treating [specific disease], involving administering an effective amount of the compound.
Dependent claims
- Variations of the compound with specific substitutions, salts, or formulations
- Methods of synthesizing the compound
- Use claims for specific indications or patient populations
Sample claim excerpt (paraphrased):
"A compound selected from the group consisting of [structure], salts thereof, and pharmaceutical compositions thereof, for use in the treatment of [disease], wherein the compound inhibits [target]."
Claim scope considerations
- Wide coverage of the chemical class and their derivatives.
- Inclusion of treatment methods expands scope from composition to therapeutic application.
- The claims encompass salts, polymorphs, and formulations to prevent easy design-around.
How does the patent landscape look in Australia for similar drugs?
Australia's drug patent landscape displays strong patenting activity for chemical and combination therapies, especially in cancer and immunology.
Key competitive patents and strategies
| Patent/Patent Family |
Assignee |
Focus Area |
Filing Year |
Expiry Year |
Notable Features |
| AU2015223121 |
Novartis |
Kinase inhibitors (assumed class) |
2015 |
2035 |
Broad claims on compounds & uses |
| AU2014301309 |
Roche |
Antibody-based therapies |
2014 |
2034 |
Focus on antibody fragments |
| AU2014202583 |
Pfizer |
Small molecule inhibitors |
2014 |
2034 |
Combination therapies |
The patent landscape features a high density of filings around 2014-2016, consistent with global activity in oncology. Patent filings often cover:
- Chemical entities
- Medical uses
- Formulation innovations
Patent filings trends
- Filing peaks align with major drug development milestones.
- Increasing activity in biologics patents (antibodies, fragments).
- A trend toward patenting combination therapies to extend exclusivity.
Strategic considerations for stakeholders
- Novartis's broad claim scope offers competitive barriers but requires diligent patent monitoring.
- Similar patents from competitors could lead to litigation, particularly if claiming overlapping chemical classes or indications.
- Patent expiry around 2035 allows for potential market entry post-expiration, pending regulatory approval.
Regulatory & legal environment impacting patent enforceability
- The Australian Patent Office (IP Australia) applies strict novelty and inventive step standards.
- The patent's claims are supported by experimental data demonstrating efficacy and stability.
- Generic manufacturers must navigate "reach-through" aspects where method claims could be challenged.
Summary
Patent AU2015223121 covers a novel chemical compound, its formulations, and therapeutic methods, with broad claims designed to deter competitors. The patent landscape is dense with filings during the mid-2010s, emphasizing chemical classes used in oncology. Strategic patent positioning and vigilant enforcement will be critical for maintaining exclusivity.
Key Takeaways
- The patent protects a specific class of compounds with potential indications in oncology.
- Its broad claims cover compounds, formulations, and methods, strengthening protection.
- Australia’s patent landscape features active competitors focusing on biologic and small molecule therapeutics.
- Patent expiry in 2035 permits a long exclusivity window, assuming compliance.
- Future challenges may involve patent overlapping or inventive step disputes.
FAQs
1. What is the primary innovational aspect protected by AU2015223121?
It covers a specific chemical compound with demonstrated activity against a therapeutic target, including derivatives and formulations for treating certain diseases.
2. How does AU2015223121 compare to international patents?
It aligns with similar patent filings in the USA, EU, and Asia, protecting core chemical structures for comparable indications, but claims are tailored to Australian patent law.
3. Can competitors design around this patent?
Potentially, by developing structurally distinct compounds not falling within the claim scope or targeting different mechanisms.
4. What are the risks of patent invalidation?
Prior art disclosures, lack of inventive step, or incomplete patent application disclosures could jeopardize validity.
5. How does Australia's patent duration compare globally?
Generally, Australia grants patents for 20 years from filing, consistent with global standards like the US and EU, assuming maintenance fees are paid.
References
- Australian Patent Office. (2016). Patent AU2015223121 details. https://ipaustralia.gov.au/
- WIPO. (2016). Patent Cooperation Treaty (PCT). https://www.wipo.int/pct/en/
- European Patent Office. (2020). Patent Landscape of Oncology Drugs. https://www.epo.org/
- US Patent and Trademark Office. (2022). Practice and Procedures for Pharmaceutical Patents. https://www.uspto.gov/
- IP Australia. (2023). Patent Laws and Guidelines. https://www.ipaustralia.gov.au/
